StockVS

Translational Development Acquisition Corp. (TDAC) 股票分析

金融服务

Translational Development Acquisition Corp.

$10.64

+$0.00 (+0.00%)

最后更新: 2026年5月26日

价格走势

分析

公司概述

Translational Development Acquisition Corp. operates as a shell company with no significant current operations, intending to execute a business combination such as a merger, amalgamation, share exchange, or asset acquisition with one or more target businesses. The entity is classified within the Financial Services sector and specifically the Shell Companies industry, a classification that signifies its status as a publicly traded vehicle awaiting a merger rather than an operating business with established revenue streams. The company's market capitalization stands at $232.22M, while its annual revenue is listed as N/A due to the lack of significant operational activity, and the employee count is N/A. These financial dimensions indicate that the company's primary value proposition derives from its potential future business combination rather than existing cash flows or operational scale, positioning it as a strategic vehicle for investors seeking exposure to a future merger event rather than current earnings performance.

财务健康

The company reports a Net Income of $6.36M over the trailing twelve months, whereas Revenue and EBITDA are both N/A, creating a financial profile where profitability metrics exist without corresponding revenue or operational earnings before interest, taxes, depreciation, and amortization. This discrepancy suggests a cost structure driven by non-operational items or accounting adjustments typical of SPACs, as the gap between nominal revenue and reported net income reveals significant reliance on other comprehensive income or specific corporate expenses not tied to traditional sales. Free Cash Flow stands at $-254,185, indicating a negative cash position that limits the company's immediate financial flexibility for organic growth or capital expenditures prior to a merger. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting that the company has not yet generated revenue to establish traditional margin performance or that its costs are structured differently than operating businesses. Total Cash holdings amount to $29,787, which are significantly lower than the Debt liability of $200,000, and the Debt to Equity ratio is N/A due to the absence of equity data in standard calculations. The balance sheet appears leveraged in a traditional sense, though the nature of this debt differs from operating leverage in a revenue-generating firm. The Current Ratio is 0.07, a figure that indicates severe short-term liquidity constraints, as current assets are far less than current liabilities, posing a risk for meeting immediate obligations without external financing. Return on Assets is -0.3%, while Return on Equity is N/A, revealing that management has not yet demonstrated effectiveness in generating returns on assets or equity in the traditional sense.

估值评估

The Trailing P/E Ratio is 36.55, while the Forward P/E is N/A, implying that the market is valuing the company based on historical earnings that may not reflect future expectations due to the lack of projected earnings data for a SPAC. The Price to Book ratio is -7.54, indicating a negative valuation relative to book value, which suggests the market prices the company below its net asset value or reflects the high risk associated with its shell status. Both the Price to Sales and EV/EBITDA metrics are N/A, as the company lacks significant sales or EBITDA, rendering these alternative valuation multiples inapplicable for assessing fair value in the traditional sense. The 52-week High is $10.60 and the 52-week Low is $10.08, meaning the current price sits within a narrow trading band only $0.52 wide, showing limited price movement over the past year. The Beta is N/A, which implies that the stock's volatility relative to the broader market cannot be quantified using standard historical data, often a characteristic of low-volume or newly listed shell companies.

Growth & Income

Revenue Growth and Earnings Growth rates are both N/A, indicating that the company has no historical growth trajectory to analyze as it has not yet generated significant revenue or earnings. Since the company does not pay dividends, the Dividend Yield and Payout Ratio are both N/A or 0.0%, reflecting that earnings are not distributed to shareholders but are instead retained or allocated toward the upcoming business combination. Consequently, the company reinvests all available capital into seeking a merger partner rather than paying dividends, which aligns with the standard lifecycle of a Special Purpose Acquisition Company. The overall growth and income profile is currently undefined by traditional metrics, as the asset's value is contingent entirely on the successful execution of a future merger rather than organic expansion or income generation.

同行比较

Translational Development Acquisition Corp. (TDAC) 在壳公司行业运营。以下是其与市值最接近的同行的比较:

公司 代码 市值 市盈率
Translational Development Acquisition Corp. TDAC $233.10M 38.0
Twenty One Capital, Inc. XXI $2.49B N/A
Churchill Capital Corp X CCCX $711.00M N/A
Drugs Made In America Acquisition II Corp. DMII $641.46M 77.5

壳公司行业平均市盈率为82.8倍。Translational Development Acquisition Corp.的市盈率为38.0。

本分析由AI生成,仅供参考,不构成投资建议。数据可能存在延迟或不准确。在做出投资决策之前,请务必进行自己的研究并咨询合格的财务顾问。

关于Translational Development Acquisition Corp.

Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.

公司简介以英文显示。

访问官网 →

关键指标

市值
$233.10M
市盈率
38.00
52周最高
$10.69
52周最低
$10.19
平均成交量
8.82K

数据由Yahoo Finance通过yfinance提供。每日更新。

公司信息

交易所
NASDAQ
国家
United States